This report on global novel drug delivery systems (NDDS) studies the overall market scenario, the ongoing trends, future commercial prospects and the competition in the novel drug delivery systems market. For the purpose of this study, the global novel drug delivery systems market is studied for route of administration type, carrier type, and geographical distribution. This study estimates the future prospects of the NDDS, post introduction of certain novel drug delivery systems market.
Based on route of administration types, the global novel drug delivery systems market is categorized into oral, injectable, pulmonary, transdermal and other segments. The market estimates in terms of revenue forecast for each of these segments since their product launch until the year 2023 are provided in this study, along with their respective CAGRs for the corresponding periods through 2023.
Based on carrier types, the global novel drug delivery systems market is categorized into liposomes, nanoparticles, microspheres, monoclonal antibodies, and others (niosomes and resealed erythrocytes as drug carriers). The market estimates in terms of revenue forecast for each of these segments since their product launch until the year 2023 are provided in this study, along with their respective CAGRs for the corresponding periods through 2023.
The novel drug delivery systems market has been geographically categorized into major regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, and Japan. Market size and forecast for these segments during 2013 to 2023 and their CAGRs for the period 2016 to 2023 are provided in this report.
Apart from the quantitative information, this report includes qualitative information sets such as drivers, challenges and opportunities, market inclination insights, major commercial events, device mechanism of artificial pancreas device systems, and benefits to the stakeholders in this market. This report also includes tools such as attractive investment proposition, Porter’s Five Forces model and market positioning of key players to assess the overall market competition. This report concludes with profiles of certain market players that have a foothold in the global novel drug delivery systems market.
The major key players profiled in the novel drug delivery systems market are on the basis of various characteristics such as business description, financial health and budget allocation, product portfolio, and news coverage. The major players profiled in this report include 3M Company, Abbott Laboratories Ltd., Amgen Inc., AstraZeneca Plc, Bausch & Lomb, Baxter International Inc., Bayer AG, Boehringer Ingelheim, Boston Scientific, Bristolmyers Squibb, Celgene Corporation, Cephalon, Inc., Genentech Inc., Genzyme Corporation, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi SA, and Teva Pharmaceutical Industries Ltd.
Type of Carrier Segmentation Analysis
In base year 2015, the liposomes and microspheres collectively attribute the largest share in the market in terms of revenue (USD). According to market experts liposomes have the distinct advantages of being both nontoxic and biodegradable as they are composed of naturally available substances. The key factors assisting the growth of liposomes market are such as, biologically active materials encapsulated within liposomes are protected to varying extent from immediate dilution or degradation which assists drug carrier systems for the transport of drugs and other bioactive capsules to disease-affected organs. In addition, the unique ability of liposomes to entrap drugs both in an aqueous and a lipid phase make such delivery systems attractive for hydrophilic and hydrophobic drugs. On the other hand microspheres posses several advantages such as they facilitate accurate delivery of small quantities of potent drug and reduced concentration of drug at desired site, and provide protection for unstable drug before and after administration prior to their availability at site of action. Thus, liposomes and microspheres are observed as the largest markets in novel drug delivery systems.
Route of Administration Type Segmentation Analysis
In base year 2015, injectable and oral drug delivery systems together accounted for more than half of the overall market share in novel drug delivery systems market. Oral drug delivery systems possess advantages associated with cost efficient manufacturing, safest and most convenient route of administration. However, protein- and peptide-based face difficulty to cross mucosal surfaces and biological membranes through several ongoing research studies the market for oral drug delivery systems in novel drug delivery systems market is expected to grow during the forecast period. Injectable drug delivery systems are most preferred drug delivery systems as they meet many benefits over other dosage forms in many cases such as unconsciousness, nausea, in emergency clinical episodes. The injectable administration route is the most common and efficient for delivery of active drug substances with poor bio-availability and the drugs with a narrow therapeutic index.
In base year 2015, North America accounted for the largest share in the global novel drug delivery systems market, followed by Asia-Pacific, Europe, LATAM and MEA. The Asia-Pacific region (comprising Japan, China and India as major countries) is anticipated to grow at the fastest CAGR during the forecast period 2016 - 2023. The key factors such as enormous rising demand and acceptance for novel drug delivery systems from people, supportive government policies, and physicians preferring novel drug delivery systems over traditional drug delivery system in North America and Europe are expected to drive the market throughout the forecast period 2016 - 2023. Asia Pacific was anticipated to project significant growth during the forecast period due to increasing government support for novel drug delivery systems, rising awareness related to novel therapies and developing healthcare infrastructure.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Novel Drug Delivery Systems (Ndds) market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Route of Administration Type
| |
Carrier Type
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
